Skip to main content
Premium Trial:

Request an Annual Quote

Veritas Bio Gets European Patent on Delivery Technology

Premium

Veritas Bio said this week that the European Patent Office has granted the company a patent covering its nucleic acid-delivery technology.

The patent, granted on patent application No. 07873598.21401, is entitled "In Vivo Delivery of Nucleic Acids," and covers the transfection of nucleic acids into skin or muscle cells. A US patent application on the technology was recently issued a notice of allowance.

As reported by Gene Silencing News, Vertias was established by the co-founders of defunct expressed RNAi drug firm Nucleonics as a holding company for the delivery technology while they look for parties interested in licensing the intellectual property (GSN 4/18/2013).

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.